GSK US

We are uniting science, technology and talent to get ahead of disease together.

Our community guidelines:

[GSK US @GSKUS]

#News for #Investors and #Media:
Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: https://t.co/ZrSf9EHCh5

[GSK US @GSKUS]

@ChronicBttrfly Hi Heather, we're sorry to hear that. In the interest of patient safety, we have forwarded your comment to our safety team. Please get in touch with us at 888-825-5249 or https://t.co/rpRwoRasMG so we can learn more about the experience you reported. Thank you.

[GSK US @GSKUS]

On World Hepatitis Day, we’re raising awareness of viral hepatitis and recognizing the importance of early and more complete testing in hepatitis B.

Learn more about complete testing at: https://t.co/ekh9rDyv9p

#WorldHepatitisDay #HepB #HepatitisB #LiverHealth #TestingMatters

[GSK @GSK]

Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.

[GSK @GSK]

News for #Investors and #Media

Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.

Find out more: https://t.co/GvGXOj21w6

#Q2Results $GSK

[GSK @GSK]

#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.

Find out more in the press release: https://t.co/SdjPEQdZc3

Our mission: to leave no person living with HIV behind.

[GSK US @GSKUS]

#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs).

With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.

Learn more: https://t.co/00v7iAtnBv

[GSK US @GSKUS]

#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: https://t.co/BhBJ8aEkmL

[GSK @GSK]

#News for #investors and #media:

We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.

Find out more: https://t.co/r7yUaG73LP

[GSK US @GSKUS]

#News for #investors and #media:
We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: https://t.co/cq4r2CkLYB.

[GSK US @GSKUS]

Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management.

At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.

[GSK @GSK]

News for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSNews for #Investors and #Media

Explore the key highlights from our Q1 2026 results announcement ⤵️

Find out more: https://t.co/XKCVX2xe4N $GSK

[GSK @GSK]

News for #Investors and #Media

Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026.

Find out more: https://t.co/pcb6qYzkHJ

$GSK #Q1Results

[GSK US @GSKUS]

@4xuHkAOxS29TACZ Hi Hussein, thanks for reaching out. We'd love to help but industry regulations mean we're not able to discuss our medicines with you. Your doctor or healthcare professional will be best placed to support. We hope this helps.

[GSK US @GSKUS]

News for #Investors and #Media: Today, we announced the US Food and Drug Administration accepted our application for a potential first-in-class treatment for chronic hepatitis B. Learn more: https://t.co/NKYLlYNMcr

[GSK US @GSKUS]

Hello Anil. Thank you for reaching out to us, we understand your frustrations. Please contact our US Response Center at 888-825-5249. They are available Monday - Friday, from 8:00am to 5:30pm (EST). We hope this helps and encourage you to reach out to them for further assistance. Thank you.

[GSK US @GSKUS]

Current treatments for #cUTIs caused by drug-resistant organisms often require hospitalization. The lack of oral treatments can result in extended hospital stays, ultimately having a negative impact on patients’ quality of life.

We remain focused to address the growing issue of antimicrobial resistance.

#ESCMIDGlobal2026

[GSK US @GSKUS]

#News for #Investors and #Media: At #SGO2026, we presented new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: https://t.co/s6OODdIBk2.

[GSK US @GSKUS]

@anilguptamd Hello Anil, thanks for your message. Your local GSK team will be best placed to support with your enquiry. Find out how to get in touch: https://t.co/r8m0DFwAEe. We hope this helps.